Skip to Content

ApoGen Receives $7 Million Investment for Cancer Therapy

Researcher with pipettes and petri dishes

A University of Minnesota startup recently attracted a major investment to support continued development of drug therapies that make cancer treatments more effective.

ApoGen Biotechnologies Inc., launched in October 2014, announced last month that it had received $7 million from life science investment firm Accelerator Corporation to continue developing a new class of drugs that slows the evolution of cancer cells and to move these treatments toward clinical trials. ApoGen is based on discoveries by two U researchers: Reuben Harris, Ph.D., professor of biochemistry, molecular biology and biophysics; and Daniel Harki, Ph.D., assistant professor of medicinal chemistry. John Santini Jr., Ph.D., is the company’s president and CEO.

Cancer therapies often become less effective over time as cancer cells become resistant to treatment. ApoGen’s drugs are designed to block a key enzyme that causes drug resistance, potentially making current and future treatments more effective.

“I have been working with Drs. Harris and Harki to move ApoGen’s science toward clinical and commercial development, and I am thrilled to now partner with Accelerator Corporation,” Santini said in a press release. “We believe that we have assembled the ideal team to advance our therapeutic technologies to slow or stop tumor evolution, which has the potential to yield a significant clinical impact for cancer patients.”

Russ Straate, associate director of the Venture Center, part of the U’s Office for Technology Commercialization, said Accelerator Corporation’s investment marks a milestone for ApoGen.

“For a startup that aims to develop a therapy based on innovative research and bring it to market, an investment like this is crucial,” Straate said. “This funding will help ApoGen in its next steps toward clinical trials and move it closer to the ultimate goal of getting this unique cancer therapy into the hands of those who can benefit from it.”

For more on the Accelerator Corporation’s investment in ApoGen, see the College of Biological Sciences blog.

Kevin Coss

Kevin Coss

Kevin is a writer and public relations associate with the Office of the Vice President for Research.

coss@umn.edu

Latest Blog Posts

Healthcare Startup Day Minnesota

The US Department of Health and Human Services visited Minnesota this month to explore collaboration with startups, industry, and academic researchers.

Read More
Suburban neighborhood

Public health researchers found girls who moved to better neighborhoods from high-poverty public housing reduced their binge drinking, while boys increased theirs.

Read More
Aquatic invasive plant

The AIS Detectors program enlists passionate citizens to help protect the pristine waters they call home from the threat of aquatic invasive species.

Read More
Youth sitting in group discussion

The startup, which creates interactive games to help educators teach core concepts in engaging ways, received $1.1 million in federal funding for the project.

Read More